Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application-Reference-Cited by-同舟云学术

Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application

Published:2021-01-06 Issue:2 Volume:112 Page:751-759
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Takeuchi Masashi¹,Imamura Chiyo K.²³^ORCID,Booka Eisuke¹⁴,Takeuchi Hiroya⁵,Mizukami Takuro⁶,Kawakami Takeshi⁷,Funakoshi Taro⁸,Wakuda Kazushige⁹^ORCID,Aoki Yu¹⁰,Hamamoto Yasuo¹⁰^ORCID,Kitago Minoru¹,Kawakubo Hirofumi¹,Boku Narikazu¹¹,Tanigawara Yusuke²,Kitagawa Yuko¹

Affiliation:

1. Department of Surgery Keio University School of Medicine Tokyo Japan

2. Department of Clinical Pharmacokinetics and Pharmacodynamics Keio University School of Medicine Tokyo Japan

3. Advanced Cancer Translational Research Institute Showa University Tokyo Japan

4. Department of Surgery Saiseikai Yokohamashi Tobu Hospital Kanagawa Japan

5. Department of Surgery Hamamatsu University School of Medicine Shizuoka Japan

6. Department of Clinical Oncology St. Marianna University School of Medicine Kanagawa Japan

7. Department of Gastrointestinal Oncology Shizuoka Cancer Center Shizuoka Japan

8. Department of Therapeutic Oncology Graduate School of Medicine Kyoto University Kyoto Japan

9. Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan

10. Division of Gastroenterology and Hepatology Department of Internal Medicine Keio University School of Medicine Tokyo Japan

11. Department of Gastrointestinal Medical Oncology National Cancer Center Tokyo Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14758

Reference34 articles.

1. Antitumor activity of 1 M tegafur‐0.4 M 5‐chloro‐2,4‐ dihydroxypyridine‐1 M potassium oxonate (S‐1) against human colon carcinoma orthotopically implanted into nude rats;Shirasaka T;Cancer Res,1996

2. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

3. Taiho Pharmaceutical.TS‐1 prescribing information in Japan; TS‐1 combination OD tablet. Ver. 4; July 2014.

4. Taiho Pharmaceutical.TS‐1 prescribing information in Singapore. Revised: TS‐ONE capsule;2013.

5. European summary of product characteristics Teysuno.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/001242/WC500104415.pdf. Accessed April 20 2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022;International Journal of Clinical Oncology;2023-08-12

2. Anticancer drug therapy for patients with renal dysfunction;International Journal of Clinical Oncology;2023-03-28

3. Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001);Gastric Cancer;2022-06-29

4. Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials;Gastric Cancer;2022-03-31